Health & Medicinearticle2026-11-15

Finerenone in Patients with Focal Segmental Glomerulosclerosis

0 citations

Abstract

Background: Mineralocorticoid receptor overactivation is implicated in podocyte injury and glomerulosclerosis. In a prespecified analysis of the FIND-CKD trial, we examined the efficacy and safety of finerenone in participants with focal segmental glomerulosclerosis (FSGS). Methods: The FIND-CKD trial randomized 1584 adults with nondiabetic CKD (eGFR ≥25 to <60 ml/min/1.73 m 2 and urinary albumin-to-creatinine ratio [UACR] ≥200 to <500 mg/g, or eGFR ≥25 to <90 ml/min/1.73 m 2 and UACR ≥500 to ≤3500 mg/g) on stable renin-angiotensin system inhibition, 1:1 to finerenone (10 or 20 mg) or placebo. Reported outcomes include total eGFR slope (baseline to month 32; FIND-CKD primary outcome), a kidney composite (sustained ≥57% eGFR decline from baseline or kidney failure; FIND-CKD secondary outcome), changes in urinary protein-to-creatinine ratio (UPCR; exploratory outcome), and adverse events (safety outcome). Results: Among the 215 participants with FSGS, mean (SD) baseline eGFR was 45 (17) ml/min/1.73 m 2 , and median (Q1, Q3) UPCR was 1427 (947, 2120) mg/g; 50% each had primary (n=108) and secondary (n=107) FSGS. Finerenone reduced the total eGFR slope versus placeboby 1.3 ml/min/1.73 m 2 /year (95% CI, 0.5–2.2; P =0.002). This effect was consistent among the 167 (78%) participants with a biopsy-proven FSGS diagnosis (1.4 ml/min/1.73 m 2 /year), and among participants with primary or secondary FSGS ( P -interaction 0.84). Finerenone yielded a hazard ratio of 0.58 (95% CI, 0.30–1.15) versus placebo for the kidney composite outcome. From baseline to month 12, finerenone lowered UPCR by 41% (95% CI, 26%–53%) versus placebo and increased the likelihood of achieving UPCR <700 mg/g (odds ratio at month 12: 6.8 [95% CI, 3.0–17.2]). A post hoc exploratory proteomics analysis showed that finerenone versus placebo reduced markers of fibrosis, inflammation, and components of the filtration barrier. Hyperkalemia-related adverse events occurred in 15 (15%) and 23 (20%) participants assigned to finerenone or placebo, respectively. Conclusions: Finerenone was well-tolerated and preserved kidney function, lowered proteinuria, and reduced markers of fibrosis, inflammation, and components of filtration barrier in FIND-CKD participants with FSGS.

// Source

View paper (DOI)OpenAlexJournal of the American Society of NephrologyPublished 2026-11-15

Authors: Hiddo J.L. Heerspink, Brendon Lange Neuen, Rajiv Agarwal, David Z.I. Cherney, Carolyn S.P. Lam, Katherine R. Tuttle, Christoph Wanner, Pantelis A. Sarafidis, Glenn Matthew Chertow, Tim Friede, Jonathan Barratt, Jürgen Floege, Alfredo Chew‐Wong, Vladimir Dobronravov, Susanne B. Nicholas, Hirokazu Okada, David Packham, Pablo E. Pérgola, Marijn M. Speeckaert, 汤水福, Niels Jongs, Johannes David Smeijer, Carolina Aldworth, Mario Berger, MEIKE DANIELA BRINKER, Rania Dayoub, Marina Yael Finkelsztein, Aidan MacNamara, Patrick Schloemer, Vlado Perkovic, for the FIND-CKD Investigators

Institutions: University of California, Los Angeles, University of Washington, The George Institute for Global Health, University Medical Center Groningen, University of Groningen, University of Toronto, University Health Network, Universitätsmedizin Göttingen, UNSW Sydney, Ghent University, Bayer (Germany), National University of Singapore, Indiana University School of Medicine, University of Würzburg, Stanford University, Royal North Shore Hospital, Universitätsklinikum Aachen, Stanford Medicine, Saitama Medical University, Toronto General Hospital, Guangzhou University of Chinese Medicine, Aristotle University of Thessaloniki, University Hospital Regensburg, The Royal Melbourne Hospital, Duke-NUS Medical School, University of Leicester, First Pavlov State Medical University of St. Petersburg, National Heart Centre Singapore, Leicester General Hospital, Ippokrateio General Hospital of Thessaloniki, Richard L. Roudebush VA Medical Center, Bayer (United States), Renal Associates P. A.